Oxcarbazepine Tablet, Film Coated
Product Images NDC 70518-4480

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Oxcarbazepine (NDC 70518-4480). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Mm2 (Oxcarbazepine 150mg 70518 4480 01)

This is a description of an Oxcarbazepine tablet with a strength of 150 mg. The tablet is repackaged by RemedyRepack Inc. and the manufacturer is Breckenridge located in Boca Raton, FL. The instruction advises storing the medication at 20-25°C with permitted excursions to 15-30°C, and keeping it out of reach of children. The NDC number for this tablet is 70618-4480-01.*

FDA Label Image

Remedy_label (Remedy Label)

This is a description of Oxcarbazepine tablets in 150 mg strength, with a quantity of 100 per box. The tablets are oval and brown in color, and are repackaged by RemedyRepack Inc. The National Drug Code (NDC) is 70518-4480-00. The medication is produced by Breckenridge in Boca Raton, FL. It is recommended to keep the medication out of reach of children and store at 20-25°C (68-77°F) with excursions allowed to 15-30°C (59-86°F) as per USP guidelines.*

FDA Label Image

Chemical Structure (Oxcarbazepine 01)

FDA Label Image

Figure 1 (Oxcarbazepine 02)

This is information about the exit rate data analysis using a log-rank test, which resulted in a p-value of 0.0001. The data illustrates the comparison between Oxcarbazepine and Placebo treatments over a trial period from Day 2 to Day 11, with time points indicated from 0 to 9 days. The experiment assessed the effectiveness of these treatments at specific time points throughout the trial.*

FDA Label Image

Figure 2 (Oxcarbazepine 03)

Seizure rate log-rank test result indicates a significant p-value of 0.046. The data seems to represent the days from the first dose to the first seizure in a study comparing Oxcarbazepine to Placebo as treatment groups.*

FDA Label Image

Figure 3 (Oxcarbazepine 04)

FDA Label Image

Figure 4 (Oxcarbazepine 05)

The text provides information on the exit rate and log-rank test results with a p-value of 0.0001. It also includes a graph showing time to exit in days for a treatment group labeled as "HIGH."*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.